Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Shanghai Institute Of Nutrition And Health Chinese Academy Of Sciences is active in the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This action is being handled by 1 distinct examiner, STEELE, AMBER D, in 1 distinct art unit. STEELE, AMBER D is the busiest examiner with 1 busiest examiner pending. This indicates that the company's current prosecution is entirely managed by a single individual. The focus on 1 distinct art unit suggests the technology is specialized.
With only 1 pending office action, the company's interaction with the USPTO is limited but highly concentrated. Practitioners should focus on the specific requirements and history of the 1 distinct examiner involved. The absence of multiple examiner perspectives means there is no internal baseline for comparing examiner behavior. Every interaction with STEELE, AMBER D is critical, as there are no other active matters to balance the portfolio's progress. This concentration means that the company's immediate patent prospects are shaped by a single individual's interpretation within the 1 distinct art unit. For a portfolio of this scale, the administrative overhead is minimal, but the strategic importance of the single examiner is high.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEELE, AMBER D | 1 | 58.9% | +9.3% |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17641539 | APPLICATION OF NON-IGF1R-BINDING SUBSTANCE IN PREVENTION AND/OR TREATMENT OF INFLAMMATORY DISEASES | STEELE, AMBER D | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Aug 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial